Abbreviations used in this paper: ARF, ADP-ribosylation factor; BFA, brefeldin A; DCV, dense-core vesicle; hGH, human growth hormone; PH, pleckstrin homology; PIP~2~, phosphatidylinositol 4,5-bisphosphate; PIP5KI, phosphatidylinositol 4-phosphate 5-kinase type I.

Introduction
============

The release of neurotransmitters from neural and neuroendocrine cells is mediated by the exocytotic fusion of synaptic vesicles and dense-core vesicles (DCVs) with the plasma membrane in a process activated by cytoplasmic Ca^2+^ elevations ([@bib40]). Secretory vesicles dock at the plasma membrane and undergo priming, which confers competence for Ca^2+^-triggered fusion ([@bib41]). Identification of phosphatidylinositol transfer protein and the phosphatidylinositol 4-phosphate 5-kinase type I (PIP5KI) as factors required for ATP-dependent priming indicated that phosphatidylinositol 4,5-bisphosphate (PIP~2~) is essential for the Ca^2+^-dependent exocytosis of docked DCVs ([@bib16]; [@bib22]; [@bib23]). A type II PI 4-kinase on DCVs ([@bib48]; [@bib5]) and a cytosolic or plasma membrane type I PIP5K ([@bib23]; [@bib47]) have been implicated in the synthesis of plasma membrane PIP~2~ ([@bib24]) required for DCV exocytosis.

Plasma membrane PIP~2~ is also essential for mediating the sequential recruitment of adaptor and accessory proteins to sites of clathrin-dependent endocytosis ([@bib12]). The requirement for PIP~2~ as a cofactor for both endocytosis and exocytosis suggests that its synthesis at localized sites of fission and fusion is tightly regulated, but little is known about the control of PIP~2~ synthesis. Recent analyses identified protein kinases and phosphatases that regulate the type I PIP5K ([@bib34]). An important advance was the finding that ADP-ribosylation factor (ARF) GTPases directly activate type I PIP5K enzymes ([@bib25]; [@bib27]).

The ARF proteins are GTPases that function as regulators of membrane traffic ([@bib39]). ARF6, the sole member of the class III ARF family, resides on endosomes and the plasma membrane and regulates membrane traffic between these compartments ([@bib14]; [@bib35]). ARF6 functions as a switch that cycles through GTP for GDP exchange and GTP hydrolysis. Correspondingly, studies of its function have used expression of dominant-negative GTP-binding deficient mutants (e.g., ARF6^T27N^) or of constitutively active GTPase-deficient mutants (e.g., ARF6^Q67L^) to perturb membrane trafficking. Activation of ARF6 promotes peripheral actin assembly ([@bib43]), plasma membrane protrusions and invaginations ([@bib35]; [@bib15]), pinocytosis ([@bib8]), and the internalization of plasma membrane proteins via clathrin-dependent ([@bib14]; [@bib1]; [@bib11]; [@bib33]) or clathrin-independent ([@bib38]; [@bib37]; [@bib8]; [@bib13]) endocytosis.

Unlike the results in other cell types, ARF6 was reported to localize to DCVs in adrenal chromaffin cells and to undergo translocation from DCVs to the plasma membrane in response to the stimulation of exocytosis ([@bib19]; [@bib9]). Whether ARF6 plays a direct role in regulated DCV exocytosis or exerts indirect effects through cytoskeletal rearrangements or plasma membrane-endosomal trafficking remains to be determined. We found that ARF6 localizes to the plasma membrane and recycling endosomes, but not to DCVs in neuroendocrine PC12 cells. Cells expressing the GTPase-deficient ARF6^Q67L^ mutant exhibited reduced rates of Ca^2+^-triggered DCV exocytosis resulting from the diversion of plasma membrane PIP~2~ and PIP5K to endosomal membranes. The restoration of DCV exocytosis by addition of PIP5K to permeable cells required Ca^2+^, which activated PIP5K and increased its association with ARF6. These results indicate that ARF6 plays a role in DCV exocytosis by controlling the activity of PIP5K and the synthesis of a required plasma membrane pool of PIP~2~.

Results
=======

Expression of ARF6^Q67L^ inhibits Ca^2+^-activated DCV exocytosis in PC12 cells
-------------------------------------------------------------------------------

To determine if ARF6-dependent cellular activities play a role in Ca^2+^-activated DCV exocytosis, wild-type and mutant ARF6 proteins (GTPase-deficient ARF^Q67L^ or GTP binding--deficient ARF6^T27N^) were expressed in PC12 cells ([Fig. 1](#fig1){ref-type="fig"} B). Human growth hormone (hGH), which is stored in DCVs, was coexpressed to enable the detection of regulated secretion in the transfected cells ([@bib50]). Ca^2+^-dependent hGH secretion was elicited in brief incubations in high K^+^-containing buffer to promote Ca^2+^ influx, and was compared with basal secretion in Na^+^-containing buffer. Expression of wild-type and GTP binding--deficient ARF6^T27N^ did not affect the basal release of hGH, but expression of the GTPase-deficient ARF6^Q67L^ increased basal release approximately twofold ([Fig. 1](#fig1){ref-type="fig"} A, open bars), which may correspond to the Ca^2+^-independent, GTP-dependent stimulation of DCV exocytosis characterized in permeable PC12 cells ([@bib3]). Ca^2+^ influx--dependent hGH secretion stimulated by K^+^ depolarization was unaffected by expression of either wild-type or ARF6^T27N^, but was consistently inhibited in ARF6^Q67L^-expressing cells ([Fig. 1](#fig1){ref-type="fig"} A, closed bars). The Ca^2+^-dependent release of hGH, calculated by subtracting basal release from high K^+^-induced release measured in the presence of high K^+^, was inhibited by 43% (24.4 ± 1.1% and 13.8 ± 2.8% hGH release for wild-type and ARF6^Q67L^, respectively). Because ARF6^Q67L^, reported to alter peripheral membrane trafficking in other cell types, affected DCV exocytosis in PC12 cells, subsequent analyses were undertaken to determine the basis for the inhibition.

###### 

**ARF6^Q67L^ localizes to plasma membrane and endosomes in PC12 cells and inhibits Ca^2^** ^**+**^ **-dependent DCV exocytosis.** PC12 cells were transfected with pcDNA3 (mock), pXS-ARF6^WT^, ARF6^Q67L^, and ARF6^T27N^ plasmids along with plasmid encoding hGH. (A) 48 h after transfection, cells were incubated for 20 min with calcium-free Locke\'s solution (control) or a depolarizing concentration of K^+^ (stimulated), and hGH release was determined (mean values ± SEM, *n* = 9). Data are respresentative of three independent experiments, and statistically significant (P \< 0.005) differences are marked by asterisks. (B) Western blots showing similar expression levels for HA-ARF6^WT^ and HA-ARF6^Q67L^ proteins and a lower level for the HA-ARF6^T27N^ protein. CAPS was detected as a loading control. (C) Intracellular distribution of hGH and chromogranin B (CgB) in transfected PC12 cells. Cells expressing indicated HA-tagged ARF6 proteins and hGH were analyzed by indirect immunofluorescence with HA (for ARF6, red) and hGH (green) antibodies or with ARF6 (red) and CgB (green) antibodies. Arrowheads indicate docked hGH- or CgB-containing DCVs that lack ARF6, and arrows indicate ARF6-positive cytoplasmic vesicles that lack hGH and CgB. Insets show magnified boxed regions. Bar, 5 μm.
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Expression of wild-type or either of the ARF6 mutants did not affect the cellular distribution of hGH ([Fig. 1](#fig1){ref-type="fig"} C, right panels) in the Golgi or in DCVs, indicating that the synthesis and transport of hGH through the secretory pathway were unaffected by ARF6 expression. The wild-type and ARF^Q67L^ expressed proteins localized to the plasma membrane and to cytoplasmic vesicular membranes, whereas the ARF6^T27N^ protein was predominantly localized to cytoplasmic vesicular membranes ([Fig. 1](#fig1){ref-type="fig"} C, left panels), as reported for other cell types ([@bib14]; [@bib35]). ARF6-containing cytoplasmic vesicles ([Fig. 1](#fig1){ref-type="fig"} C, arrows) were readily distinguished from hGH-immunoreactive DCVs. Neither docked DCVs containing hGH ([Fig. 1](#fig1){ref-type="fig"} C, arrowheads) nor cytoplasmic DCVs ([Fig. 1](#fig1){ref-type="fig"} C, insets) colocalized with ARF6-containing cytoplasmic vesicles. Endogenous ARF6 was weakly detected in cytoplasmic vesicular membranes and on the plasma membrane ([Fig. 1](#fig1){ref-type="fig"} C), and this localization was clearly distinct from that of chromogranin B, an endogenous DCV constituent ([Fig. 1](#fig1){ref-type="fig"} C). Overall, these results indicated that ARF6 proteins are not present on DCVs, and that the inhibition of Ca^2+^-dependent DCV exocytosis by ARF6^Q67L^ was unlikely the result of either an altered DCV localization or of a direct effect of ARF6 on DCVs.

ARF6 colocalizes with transferrin- and Rab11-positive endosomes in PC12 cells
-----------------------------------------------------------------------------

In other cell types, ARF6 is present in endosomal compartments and on the plasma membrane ([@bib14]; [@bib35]; [@bib37]). Although ARF6 was reported to be present on DCVs in chromaffin cells ([@bib19]; [@bib9]), this was not the case for neuroendocrine PC12 cells ([Fig. 1](#fig1){ref-type="fig"} C). To identify the cytoplasmic vesicles containing ARF6, colocalization studies were conducted for proteins characteristic of secretory and endocytic compartments. Cytoplasmic ARF6 ([Fig. 2](#fig2){ref-type="fig"} A, arrows) did not colocalize with either TGN38 or with mannosidase II. ARF6-containing vesicles were more diffusely localized around the perinuclear region after treatment with brefeldin A (BFA; [Fig. 2](#fig2){ref-type="fig"} A), which causes tubulation of endosomes, the TGN, and lysosomes ([@bib29]). BFA treatment also affected mannosidase II--containing and TGN38-containing Golgi elements ([Fig. 2](#fig2){ref-type="fig"} A), as well as transferrin-positive endosomal compartments (unpublished data). The distributions of wild-type and ARF6^Q67L^ (unpublished data) and endocytosed transferrin, a marker for recycling endosomes, overlapped extensively, but not precisely ([Fig. 2](#fig2){ref-type="fig"} B, inset), indicating that cytoplasmic ARF6 proteins were localized to a subdomain of recycling endosomes. Consistent with this, ARF6-containing membranes colocalized extensively with Rab11-positive late endosomes ([Fig. 2](#fig2){ref-type="fig"} B, arrows). The localization of ARF^Q67L^ at the plasma membrane and in recycling endosomes suggested that the ARF6^Q67L^ inhibition of DCV exocytosis was indirect and caused by alterations in endosomal plasma membrane trafficking.

![**ARF6 localizes to the endocytic pathway in PC12 cells.** (A) PC12 cells were transfected for 48 h with wild-type EGFP-ARF6 (green) and treated with 5 μg ml^−1^ BFA where indicated (BFA). Immunocytochemistry was conducted to localize TGN38 (red) and mannosidase II (red). Arrows indicate ARF6-containing compartments that lack TGN38 and mannosidase II. (B) Top row, internalized Texas red transferrin (red) exhibits extensive colocalization with EGFP-ARF6 (green). Inset shows magnified perinuclear region. Bottom row, HA-ARF6 (red) exhibits extensive colocalization with Rab11 (green). Arrows indicate ARF6-containing compartments that colocalize with transferrin and Rab11. Bars, 10 μm.](200212142f2){#fig2}

Recruitment of PIP5K by ARF6^Q67L^ alters the cellular distribution of PIP~2~
-----------------------------------------------------------------------------

In other cell types, the expression of the GTPase-deficient ARF6^Q67L^ induces an accumulation of endosomal membranes leading to the intracellular trapping of plasma membrane constituents that normally recycle ([@bib8]; [@bib31]). We considered the possibility that a plasma membrane constituent essential for regulated DCV exocytosis was depleted from the plasma membrane in cells expressing ARF6^Q67L^. Indeed, SNAP-25, a plasma membrane SNARE required for DCV exocytosis ([@bib3]), was found to substantially relocalize to an endosomal compartment in ARF6^Q67L^-expressing cells (unpublished data); however, we were unable to rescue regulated hGH release by overexpressing SNAP-25. Another plasma membrane constituent required for DCV exocytosis is PIP~2~ ([@bib23]), and we found that plasma membrane pools of PIP~2~ were dramatically altered by ARF6^Q67L^ expression. A PLC δ1 pleckstrin homology (PH) domain--GFP fusion protein was expressed to detect membrane-associated PIP~2~ as described previously ([@bib45]). PC12 cells expressing high levels of wild-type ARF6 exhibited a uniform distribution of the PH-GFP at the plasma membrane ([Fig. 3](#fig3){ref-type="fig"} A), which colocalized with plasma membrane ARF6. In contrast, cells expressing ARF6^Q67L^ exhibited a very different distribution of the PH-GFP protein. At low expression levels, the PH-GFP localized to the plasma membrane as well as to intracellular endosomal membranes that contained ARF6^Q67L^ ([Fig. 3](#fig3){ref-type="fig"} A). Cells expressing higher levels of ARF6^Q67L^, representing ∼25% of the cell population, accumulated intracellular inclusions enriched in the PH-GFP protein as well as ARF6^Q67L^ ([Fig. 3](#fig3){ref-type="fig"} A, arrow). Plasma membrane--associated PH-GFP was markedly decreased in these cells ([Fig. 3](#fig3){ref-type="fig"} A, insets), and the cells resembled ARF6^Q67L^-expressing fibroblasts in which PIP~2~-positive vacuoles accumulated ([@bib8]). This feature was unique for ARF6^Q67L^ expression and was not observed for ARF6^WT^ or ARF6^T27N^ ([Fig. 3](#fig3){ref-type="fig"} A). Quantitation of digital images documented that the PH-domain of PLCδ1 was depleted from the plasma membrane ([Fig. 3](#fig3){ref-type="fig"} B, left) and preferentially accumulated on endosomal membranes ([Fig. 3](#fig3){ref-type="fig"} B, right) in cells expressing ARF6^Q67L^ and, to a much lesser extent, wild-type ARF6, but not ARF6^T27N^ or ARF6^N122I^, another GTP-binding--defective mutant ([Fig. 3](#fig3){ref-type="fig"} B, P \< 0.005).

###### 

**PIP~2~ redistributes from plasma membrane to endosomes in ARF6^Q67L^-expressing PC12 cells.** (A) PC12 cells were cotransfected for 48 h with plasmids encoding PH-GFP (green) and HA-tagged ARF6^WT^, ARF6^Q67L^, or ARF6^T27N^ (detected with HA antibody, red). Insets show enlarged regions of the plasma membrane. Cells expressing relatively high levels of ARF6^Q67L^ exhibited endosomal accumulation of PH-GFP (arrow) and decreased plasma membrane fluorescence (inset). (B) The fluorescence intensity of PH-GFP was quantified in 50 randomly selected cells, and the ratio of plasma membrane (left) or endosomal (right) to total fluorescence was plotted as mean values ± SEM (asterisk indicates P \< 0.005 for comparison with mock-transfected by *t* test). (C) Immunoreactive PIP~2~ (red) was detected in permeable PC12 cells expressing ARF6^WT^, ARF^Q67L^, or ARF6^T27N^ (green). Immunoreactive PIP~2~ was decreased in ARF6^Q67L^-expressing cells (arrows). (D) The fluorescence intensity of PIP~2~ antibody staining was quantified and normalized to membrane area in 50 randomly selected cells. Values are means ± SEM with asterisk corresponding to P \< 0.005 for comparison with mock-transfected by *t* test). Bar, 20 μm.
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A shift of the PH-GFP protein from plasma membrane to endosomes in ARF6^Q67L^-expressing cells implied that the distribution of PIP~2~ was markedly altered. To confirm this directly, we determined the plasma membrane content of PIP~2~ in permeable cells using a PIP~2~ antibody that revealed a punctate staining pattern ([Fig. 3](#fig3){ref-type="fig"} C, red channel). The PIP~2~ content of the plasma membrane was not altered in cells expressing ARF6^WT^ or ARF6^T27N^ ([Fig. 3](#fig3){ref-type="fig"} C), but was strongly decreased in cells expressing ARF6^Q67L^ ([Fig. 3](#fig3){ref-type="fig"} C, arrows). Quantitation of digital images documented a highly significant decrease for plasma membrane PIP~2~ in cells expressing ARF6^Q67L^ ([Fig. 3](#fig3){ref-type="fig"} D). Overall, the results indicated that ARF6^Q67L^ expression promotes a redistribution of PIP~2~ in PC12 cells from the plasma membrane to an intracellular endosomal compartment.

The preferential accumulation of PIP~2~ in an endosomal compartment might result from either the translocation of plasma membrane containing PIP~2~ or the redirected synthesis of PIP~2~ on endosomes. ARF proteins directly regulate PIP5K activity ([@bib25]; [@bib27]), and the constitutively active ARF6^Q67L^ localized to endosomes may persistently activate PIP5K on endosomal membranes. To examine this possibility directly, we coexpressed HA-tagged PIP5KIγ with ARF6-GFP and determined their distribution ([Fig. 4](#fig4){ref-type="fig"}). PIP5KIγ preferentially localized to the plasma membrane in cells expressing wild-type ARF6 or low levels of ARF6^Q67L^ where there was extensive colocalization of PIP5KIγ with the ARF6 proteins ([Fig. 4](#fig4){ref-type="fig"}). Cells expressing higher levels of ARF6^Q67L^ exhibited a striking redistribution of PIP5KIγ to intracellular membranes where the enzyme colocalized with the ARF6 protein ([Fig. 4](#fig4){ref-type="fig"}, arrow). Plasma membrane PIP5KIγ was substantially decreased in these cells ([Fig. 4](#fig4){ref-type="fig"}, insets), indicating that ARF6^Q67L^ diverts PIP5K to endosomal membranes. This redistribution of PIP5K would account for the accumulation of PIP~2~ in an endosomal compartment ([Fig. 3](#fig3){ref-type="fig"} A, arrow). The results indicated that the GTPase-deficient ARF6^Q67L^ induces a shift in the distribution of PIP5K and PIP~2~ from the plasma membrane to intracellular membranes.

![**PIP5KIγ is recruited to an endosomal compartment in ARF6^Q67L^-expressing PC12 cells.** PC12 cells were cotransfected for 48 h with plasmids encoding EGFP-ARF6 proteins (green) and HA-PIP5KIγ (detected by HA antibody, red). Insets show magnified regions of the plasma membrane. Cells expressing relatively high levels of ARF6^Q67L^ exhibited an endosomal accumulation of PIP5KIγ (arrow) and its depletion from the plasma membrane (inset). Bar, 10 μm.](200212142f4){#fig4}

Restoration of Ca^2+^-dependent exocytosis by PIP5K by a Ca^2+^-dependent mechanism
-----------------------------------------------------------------------------------

To further probe the mechanism by which ARF6^Q67L^ inhibited Ca^2+^-dependent DCV exocytosis, we determined whether inhibition was preserved in permeable PC12 cells where DCV exocytosis can be directly triggered by Ca^2+^ addition ([@bib21]). Expression of ARF6^Q67L^ (but not wild-type ARF6 or ARF6^T27N^) resulted in the inhibition of Ca^2+^-triggered hGH release by ∼48% in permeable cells ([Fig. 5](#fig5){ref-type="fig"} A, middle bars), which corresponded closely to the intact cell assay results ([Fig. 1](#fig1){ref-type="fig"} A). However, when MgATP and rat brain cytosol were included in the incubations to fully reconstitute Ca^2+^-dependent exocytosis, the inhibitory effect of ARF6^Q67L^ was not observed ([Fig. 5](#fig5){ref-type="fig"} A, right bars). This reversal of inhibition in the permeable cells was dependent on MgATP concentration ([Fig. 5](#fig5){ref-type="fig"} C) and the presence of cytosol (compare [Fig. 5](#fig5){ref-type="fig"} D with [Fig. 5](#fig5){ref-type="fig"} A).

![**The inhibition of DCV exocytosis by ARF6^Q67L^ is preserved in permeable cells and reversed in incubations containing Ca^2^** ^**+**^ **, MgATP, and cytosol.** PC12 cells were cotransfected for 48 h with plasmids encoding hGH and ARF6^WT^, ARF6^T27N^, or ARF6^Q67L^ as indicated, and permeable cell hGH secretion assays were conducted (shown as mean ± SEM, *n* = 4). (A) Inhibition of DCV exocytosis in ARF6^Q67L^-expressing cells was preserved on permeabilization, but only in incubations lacking MgATP. Incubations contained Ca^2+^, MgATP, and rat brain cytosol (RBC) as indicated. (B) Reversal of inhibition in ARF6^Q67L^-expressing cells required all three components. Two-stage secretion assays were conducted with MgATP and cytosol in priming incubations and Ca^2+^ and cytosol in triggering incubations (for times indicated). (C) Reversal of inhibition in ARF6^Q67L^-expressing cells required MgATP. Incubations similar to those in A were conducted with Ca^2+^, cytosol, and indicated concentrations of MgATP. (D) Reversal of inhibition in ARF6^Q67L^-expressing cells was not observed in the absence of cytosol. Incubations similar to those in A were conducted with Ca^2+^ or MgATP in the absence of cytosol (RBC). Asterisks indicate significant (P \< 0.01) differences with mock- transfected cells.](200212142f5){#fig5}

To determine whether MgATP and cytosol were sufficient for reversing the inhibitory effects of ARF6^Q67L^, a two-stage assay was used. MgATP- and cytosol-dependent priming reactions were conducted before Ca^2+^-triggering incubations, which contained Ca^2+^ and cytosol, but not MgATP ([@bib21]). We found that the inhibition by ARF6^Q67L^ was preserved in the two-stage assay over the entire time course of Ca^2+^-evoked hGH release ([Fig. 5](#fig5){ref-type="fig"} B). Together with the other findings, this result indicates that all three constituents, MgATP, cytosol, and Ca^2+^, but no two of these alone, were essential for restoring regulated DCV exocytosis in ARF6^Q67L^-expressing cells.

Because the reversal of ARF6^Q67L^ inhibition was dependent on MgATP and cytosol in permeable cells in which plasma membrane PIP~2~ and PIP5K had been depleted, it was very likely that the soluble PIP5K enzymes present in cytosol were responsible for the restoration of DCV exocytosis. To test the role of PIP5K directly, we attempted to rescue the inhibitory effect of ARF6^Q67L^ by expressing the type Iγ PIP5K. Expression of PIP5KIγ successfully counteracted the inhibitory effect of ARF6^Q67L^ on Ca^2+^-activated hGH release in permeable cells ([Fig. 6](#fig6){ref-type="fig"} A). As anticipated, rescue by PIP5KIγ was only evident in incubations that included MgATP and failed to occur with expression of a kinase-dead truncation mutant of PIP5KIγ Δ345 ([Fig. 6](#fig6){ref-type="fig"} A), which did not localize to the plasma membrane (unpublished data). In addition, the reversal of ARF6^Q67L^ inhibition by expression of the wild-type PIP5KIγ enzyme did not require addition of cytosol ([Fig. 6](#fig6){ref-type="fig"} A). These results indicate that reversal of ARF6^Q67L^ inhibition can be achieved by PIP5KIγ overexpression, and they imply that the factor in cytosol required for the reversal is one of the abundant cytosolic PIP5K enzymes ([@bib23]; [@bib47]). Indeed, direct addition of a pure recombinant PIP5KIγ protein to the permeable cell assay was effective in counteracting the inhibitory effects of ARF6^Q67L^ ([Fig. 6](#fig6){ref-type="fig"} B).

![**Expression or addition of PIPKIγ to permeable cells replaces cytosol in restoring DCV exocytosis in ARF6** ^Q67^ **^L^-expressing cells.** PC12 cells were transfected for 48 h with plasmids encoding hGH and either ARF6^Q67L^or PIP5KIγ as indicated, and permeable cell hGH secretion assays were conducted. (A) Expression of PIP5KIγ restored Ca^2+^-dependent hGH secretion in ARF6^Q67L^- expressing cells in the presence (but not in the absence) of MgATP. Expression of the Δ345 PIP5KIγ mutant failed to restore Ca^2+^-dependent secretion. (B) Purified PIP5KIγ replaced cytosol and restored Ca^2+^-dependent hGH secretion in ARF6^Q67L^- expressing cells. Incubations similar to those of A were conducted with Ca^2+^, MgATP, and 0.6 μg/ml (∼7 nM) PIP5KIγ where indicated. (C) Expression of PIP5KIα, but not a kinase-dead (D309N/R427Q) mutant, replaced cytosol in restoring Ca^2+^-dependent hGH secretion in ARF6^Q67L^-expressing cells in the presence (but not in the absence) of MgATP. Results are representative of at least two experiments with mean hGH values ± SEM (*n* = 4). (D) Wild-type and kinase-dead FLAG-tagged PIP5KIα proteins were expressed at similar levels and were plasma membrane localized. Immunocytochemistry with FLAG antibodies was conducted. Bar, 10 μm. Asterisks indicate significant (P \< 0.01) differences with mock-transfected cells.](200212142f6){#fig6}

Multiple isoforms of PIP5K have been characterized consisting of types Iα, Iβ, and Iγ ([@bib26]; [@bib2]). We found that expression of the type Iα (human) PIP5K also reversed the ARF6^Q67L^ inhibition, whereas the kinase-dead (D309N/R427Q) PIP5KIα failed to provide rescue ([Fig. 6](#fig6){ref-type="fig"} C). Both active and inactive enzymes were equally well expressed and associated with the plasma membrane ([Fig. 6](#fig6){ref-type="fig"} D). Expression of the type Iβ (human) PIP5K provided only weak rescue, but was poorly expressed (unpublished data). Overall, the results strongly support the conclusion that the depletion of PIP~2~ from the plasma membrane induced by long-term expression of ARF6^Q67L^ was responsible for the inhibition of regulated DCV exocytosis.

PIP5KIγ is regulated by phosphorylation- and ARF6-dependent mechanisms
----------------------------------------------------------------------

These results on PIP5K provided an explanation for why MgATP and cytosol counteracted the inhibition of exocytosis mediated by ARF6^Q67L^ expression, but they did not account for the additional requirement for Ca^2+^ in the rescue. Thus, we determined whether a requirement for Ca^2+^ in the restoration was related to the regulation of PIP5K activity. The phosphorylation of Ser214 in mouse PIP5KIα was reported to decrease lipid kinase activity, whereas PKC was reported to stimulate lipid kinase activity by promoting protein phosphatase--mediated dephosphorylation of the enzyme ([@bib34]). Thus, the requirement of Ca^2+^, in addition to MgATP and cytosol, for counteracting ARF6^Q67L^ inhibition might be mediated by the Ca^2+^-dependent activation of PKC, which may enhance PIP5K activity. Consistent with this, we found that the specific pseudosubstrate inhibitor of PKC fully blocked the reversal of ARF6^Q67L^ inhibition observed with Ca^2+^, MgATP, and cytosol in permeable cell incubations ([Fig. 7](#fig7){ref-type="fig"} A).

![**PIP5KIγ is regulated by Ca** ^2**+**^ **and dephosphorylation.** (A) The restoration of Ca^2+^-dependent hGH secretion in permeable ARF6^Q67L^- expressing cells by Ca^2+^, MgATP, and cytosol is prevented by inhibition of PKC. Permeable cell incubations were conducted 48 h after transfection with hGH- and ARF6^Q67L^-encoding plasmids. Restoration of Ca^2+^-dependent hGH release was observed with MgATP and cytosol, but not in the presence of 5 μg/ml PKC(19--31) pseudosubstrate inhibitor. (B) Expression of S264A PIP5KIγ (but not wild-type PIP5KIγ) enhanced Ca^2+^-dependent hGH secretion. PC12 cells were cotransfected with plasmids encoding hGH and wild-type or S264A PIP5KIγ as indicated. hGH release from intact cells in Na^+^ (control) or K^+^ (stimulated) buffers was determined. Asterisks indicate significant (P \< 0.05) differences with mock-transfected cells. (C) PC12 cells were probed with HA antibody to detect PIP5KIγ (green) and PIP~2~ antibody to detect PIP~2~ (red). Plasma membrane immunoreactive PIP~2~ increased in cells expressing S264A PIP5KIγ. Bar, 10 μm. (D, a) Quantitation of PIP~2~ in cells expressing PIP5KIγ or S264A PIP5KIγ. A representative density profile plot was generated using SCION Image for green channel (PIP5K, left) and red channel (PIP~2~, right). Pixel intensity was determined by a "row average plot" of a section selected from a confocal slice through the center of the cell. (D, b) The percentage of cells exhibiting average pixel intensities above 150 for immunoreactive PIP~2~ is shown for mock transfectants and cells expressing wild-type or S264A PIP5KIγ. 50 randomly selected cells of each type were quantitated.](200212142f7){#fig7}

To determine the role of dephosphorylation in the regulation of PIP5K activity, we constructed the cognate nonphosphorylatable S264A mutant of PIP5KIγ, which was anticipated to be active relative to the wild-type enzyme. Both wild-type and S264A PIPKIγ were expressed at similar levels in transfected PC12 cells, and each localized to the plasma membrane ([Fig. 7](#fig7){ref-type="fig"} D, left panels). Expression of the S264A PIP5KIγ mutant enhanced Ca^2+^-dependent hGH secretion by ∼30% ([Fig. 7](#fig7){ref-type="fig"} B), whereas expression of wild-type PIP5KIγ had little effect, consistent with the possible constitutive activity of the S264A PIPKIγ enzyme. Indeed, cells expressing the S264A mutant PIPKIγ exhibited substantially greater increases in plasma membrane PIP~2~ than those expressing the wild-type enzyme ([Fig. 7](#fig7){ref-type="fig"} C and [Fig. 7](#fig7){ref-type="fig"} Da, right). Quantitation of plasma membrane immunoreactive PIP~2~ ([Fig. 7](#fig7){ref-type="fig"} Db) indicated that \>32% of S264A PIP5KIγ-expressing cells exceeded threshold values of immunoreactive PIP~2~, compared with \<10% of wild-type PIPKIγ-expressing cells. Overall, the results indicate that phosphorylation at Ser264 may control the activity of PIP5KIγ and that plasma membrane PIP~2~ levels regulate Ca^2+^-dependent exocytosis.

ARF proteins were reported to directly activate purified type Iα (mouse) PIP5K ([@bib25]; [@bib27]) and ARF6 was shown to be recruited with PIP5K Iα to plasma membrane sites in fibroblasts ([@bib25]), but a direct interaction of ARF6 with PIP5K has not been demonstrated. To determine whether ARF6 associates with PIP5K, coimmunoprecipitation experiments were conducted ([Fig. 8](#fig8){ref-type="fig"} A). ARF6 was found to co-immunoisolate with PIP5KIγ in resting cells, and this was enhanced by Ca^2+^ influx stimulated by K^+^ depolarization ([Fig. 8](#fig8){ref-type="fig"} A, a and b). ARF6^Q67L^ and ARF6^N122I^ proteins exhibited similar associations with PIP5KIγ that were enhanced by Ca^2+^ influx ([Fig. 8](#fig8){ref-type="fig"} Ba). The results indicate that the association of ARF6 with PIP5K is regulated by a Ca^2+^-dependent mechanism.

![**ARF6 associates with PIP5KIγ.** PC12 cells were cotransfected with plasmids encoding EGFP-ARF6^WT^, EGFP-ARF6^Q67L^, or EGFP-ARF6^N122I^ and HA-tagged wild-type or S264A PIP5KIγ as indicated. (A, a) Ca^2+^ influx and dephosphorylation promote the association of ARF6 with PIP5KIγ. Cells cotransfected for 48 h with indicated plasmids were incubated in Na^+^-containing (control, CNT) or K^+^-containing (stimulated, S) buffers for 5 min. HA antibody immunoprecipitates were prepared from detergent lysates and analyzed by Western blotting for EGFP-ARF6 and HA-PIP5KIγ. Co-immunoprecipitation of EGFP-ARF6 with HA antibody was enhanced by K^+^ depolarization in PIP5KIγ-expressing cells. In S264A PIP5KIγ-expressing cells, coimmunoprecipitation was increased in resting cells and not enhanced by K^+^ depolarization. (A, b) Quantitation of ARF6 coimmunoprecipitation with PIP5KIγ from 3 experiments (± SEM) similar to that in panel a. (B) Co-immunoprecipitation studies similar to those in panel A were conducted for cells cotransfected with plasmids encoding ARF6^WT^, ARF6^Q67L^, and ARF6^N122I^ with (a) wild-type HA-PIP5KIγ or (b) HA-S264A PIP5KIγ. Values under each lane pair indicate fold stimulation by K^+^ depolarization.](200212142f8){#fig8}

To determine if this Ca^2+^-dependent mechanism involves PIP5K dephosphorylation, immunoprecipitations were conducted with cells expressing the nonphosphorylatable S264A PIP5KIγ mutant. ARF6 exhibited substantial association with the S264A enzyme in resting cells, and this was not further enhanced by K^+^ depolarization and Ca^2+^ influx ([Fig. 8](#fig8){ref-type="fig"} A, a and b). ARF6^Q67L^ and ARF6^N122I^ proteins exhibited a similar association with the S264A PIP5KIγ that was not enhanced by Ca^2+^ influx ([Fig. 8](#fig8){ref-type="fig"} Bb). The results indicate that, in addition to enhancing PIP5K activity, Ca^2+^ increases the association of PIP5K with ARF6. Interactions between ARF6 and PIP5K appear to be governed principally by the phosphorylation state of PIP5K rather than the guanine nucleotide--bound state of ARF6. The association of PIP5K with membrane-bound ARF6 may be important for targeting the enzyme to its membrane PI(4)P substrate. Overall, the results suggest a pathway by which Ca^2+^ enhances PIP~2~ synthesis for DCV exocytosis via an ARF6-dependent PIP5K ([Fig. 9](#fig9){ref-type="fig"}).

![**ARF6 regulation of Ca** ^2**+**^ **-dependent DCV exocytosis in PC12 cells.** (1) Ca^2+^ influx stimulates exocytosis of docked DCVs, but only if plasma membrane PIP~2~ is available. (2) Ca^2+^ influx promotes the dephosphorylation of PIP5KI. (3) Dephospho-PIP5KI associates with ARF6 and is activated to synthesize PIP~2~ for DCV exocytosis. (4) Increased PIP~2~ synthesis drives endocytosis and retrieval of the DCV membrane after exocytosis. (5) Constitutive endocytosis may be enhanced by ARF6^Q67L^ stimulation of PIP5K. (6 and 7) Lack of GTP hydrolysis on ARF6^Q67L^ and constitutive PIP~2~ production on endosomes prevents recycling to the plasma membrane. Entrapment of plasma membrane constituents and diversion of PIP5K and PIP~2~ to endosomes in ARF6^Q67L^-expressing cells results in the inhibition of DCV exocytosis.](200212142f9){#fig9}

Discussion
==========

Basis of the inhibition of DCV exocytosis by ARF6^Q67L^ expression
------------------------------------------------------------------

In this work, we sought to characterize the role of ARF6 in the mechanisms that regulate Ca^2+^-dependent DCV exocytosis in neuroendocrine PC12 cells. Expression of the constitutively active GTPase-deficient ARF6^Q67L^ mutant exerted a strong inhibitory effect on regulated DCV exocytosis. Subsequent analyses clarified the nature of the inhibitory effect as consisting of a diversion of plasma membrane constituents that are required for DCV exocytosis, PIP5K, and PIP~2~, to endosomal membranes with their corresponding depletion from the plasma membrane.

As reported for other cell types ([@bib14]; [@bib35]), the distribution of ARF6 proteins in PC12 cells was restricted to the plasma membrane and endosomal membranes. The restricted localization of ARF6 to these compartments in PC12 cells was unanticipated in view of the reported biochemical localization of ARF6 to the DCVs of chromaffin cells ([@bib19]; [@bib9]). However, the degree of purity of DCVs was not assessed in those experiments, and immunocytochemical localization analyses were not reported. [@bib46] reported immunocytochemical experiments in PC12 cells indicating that ARF6 proteins colocalize with DCV markers. However, there was a broad cytoplasmic distribution of both ARF6 and DCV markers by fluorescence microscopy that would preclude resolution of the clearly distinct distributions that we observed ([Fig. 1](#fig1){ref-type="fig"} C). Moreover, an immunogold electron microscopic analysis ([@bib46]) was consistent with the localization of ARF6 proteins to cytoplasmic membranes other than DCVs.

In other cell types, ARF6 traffics between endosomal and plasma membrane compartments and regulates endosome-plasma membrane trafficking. Perturbations in endosome-plasma membrane trafficking that result from expression of the constitutively active ARF6^Q67L^ mutant vary with cell type, internalized protein, time of expression, and distribution of the actin cytoskeleton ([@bib38]; [@bib37]; [@bib1]; [@bib8]; [@bib13]; [@bib33]). Long-term expression of the constitutively active ARF6^Q67L^ protein in PC12 cells resulted in the accumulation of a subset of plasma membrane constituents in an endosomal compartment. This likely resulted from both accelerated internalization as well as inhibited recycling of constituents back to the plasma membrane. Activated ARF6 likely enhances both clathrin-dependent and -independent pathways of internalization in PC12 cells. Plasma membrane SNAP-25 is co-internalized with PIP~2~-containing, ARF6^Q67L^-enriched membranes by a dynamin-independent pathway (unpublished data), but ARF6^Q67L^-expressing cells also exhibit increased initial rates of transferrin uptake (unpublished data) presumed to be via clathrin- and dynamin-mediated endocytosis. ARF6^Q67L^ expression also accelerates the formation of synaptic vesicle-like endosomes in PC12 cells ([@bib36]) that are formed by a clathrin-dependent pathway ([@bib44]). These results indicate that multiple endocytic pathways are enhanced by expression of the constitutively active ARF6^Q67L^ in PC12 cells.

ARF proteins directly activate PIP5K enzymes and regulate the synthesis of PIP~2~ ([@bib25]; [@bib27]). Plasma membrane PIP~2~ is an essential cofactor for clathrin-dependent endocytosis ([@bib4]; [@bib12]; [@bib20]), phagocytosis ([@bib7]), pinocytosis ([@bib43]; [@bib8]; [@bib20]), and endosome motility ([@bib42]; [@bib43]). Thus, constitutive activation of PIP5K by ARF6^Q67L^ could enhance the internalization of plasma membrane constituents through multiple pathways ([@bib37]; [@bib8]; [@bib11]; [@bib33]; [@bib31]). However, ARF6-GTP cycling is essential for the trafficking of recycling endosomes back to the cell surface ([@bib18]; [@bib31]). Because this fails to occur in the GTPase-deficient ARF6^Q67L^ mutant, plasma membrane constituents are entrapped in an endosomal pool ([@bib8]; [@bib13]; [@bib33]; [@bib31]). In PC12 cells expressing ARF6^Q67L^, an endosomal compartment containing ARF6^Q67L^, PIP~2~, and PIP5K formed, which resulted in the depletion of these constituents from the plasma membrane.

Plasma membrane PIP~2~ is essential for Ca^2+^-dependent DCV exocytosis at the plasma membrane ([@bib23]; [@bib24]). That the depletion of PIP~2~ from the plasma membrane in ARF6^Q67L^-expressing PC12 cells was responsible for the inhibition of DCV exocytosis was established by demonstrating that expression or addition of PIP5K was capable of restoring regulated exocytosis in permeable cells incubated with MgATP. These results accounted for the absence of inhibition in permeable cell reconstitutions in which cytosol and MgATP were included, and strongly support the conclusion that plasma membrane PIP~2~ is rate-limiting for DCV exocytosis in ARF6^Q67L^-expressing cells. These results reinforce the conclusion that PIP~2~ is essential for DCV exocytosis and indicate that ARF6 regulation of PIP5K plays a role in maintaining plasma membrane pools of PIP~2~ required for exocytosis.

Regulation of PIP5K by ARF6 for Ca^2+^-dependent DCV exocytosis
---------------------------------------------------------------

The restoration of Ca^2+^-dependent DCV exocytosis in ARF6^Q67L^-expressing permeable cells by PIP5K expression or addition explained the roles of cytosol and MgATP in the restoration, but not that of Ca^2+^. The role of Ca^2+^ in the restoration may be mediated by PKC based on the effectiveness of a specific PKC pseudosubstrate inhibitor in blocking it. Although the involvement of PKC in Ca^2+^-dependent DCV exocytosis is well established ([@bib32]; [@bib10]), its precise role and the nature of PKC substrates involved in DCV exocytosis remain unknown. [@bib34] reported that PKC contributes to the maintenance of cellular PIP~2~ levels by regulating protein phosphatase-1, which catalyzes the dephosphorylation and activation of PIP5KI. The dephospho-PIP5KIα enzyme exhibits increased lipid kinase activity in vitro ([@bib34]), and we found that the cognate nonphosphorylatable S264A PIP5KIγ enzyme was activated to synthesize plasma membrane PIP~2~ and enhance Ca^2+^-dependent DCV exocytosis in PC12 cells. This result indicates that a nonphosphorylatable, activated PIP5KIγ enzyme is a positive effector for regulated exocytosis, which is particularly significant because [@bib47] found that PIP5KIγ undergoes dephosphorylation in response to Ca^2+^ influx into synaptosomes. [@bib17] also reported that Ca^2+^ influx increases PIP~2~ synthesis in chromaffin cells. Together, these results indicate that PIP5K enzymes are Ca^2+^-dependent effectors that are activated to promote PIP~2~ synthesis at the plasma membrane.

ARF6 at the plasma membrane likely mediates the membrane targeting and localization of the activated PIP5K enzymes ([@bib25]), and we found that wild-type PIP5K exhibited an increased association with ARF6 in response to Ca^2+^ influx into PC12 cells. The Ca^2+^-dependent increase in ARF6 association may result from PIP5K dephosphorylation because the S264A mutant exhibited a strongly enhanced association with ARF6 that was not further increased by Ca^2+^ influx. These results are consistent with a model ([Fig. 9](#fig9){ref-type="fig"}) in which Ca^2+^ influx triggers the dephosphorylation of PIP5K, its increased association with ARF6, and its activation for plasma membrane PIP~2~ synthesis.

Although the ATP-dependent priming of DCVs for Ca^2+^-dependent exocytosis is known to require PIP~2~ synthesis ([@bib23]), our results provide the first indication that PIP~2~ synthesis is regulated through an ARF6-dependent Ca^2+^-triggered mechanism. The reported Ca^2+^ regulation of DCV priming ([@bib6]; [@bib40]) may in part be mediated by this ARF6-dependent pathway. The Ca^2+^-triggered stimulation of PIP5K activity, particularly of the type Iγ isoform that is enriched at synapses ([@bib47]), would play an important role in enhancing Ca^2+^-triggered exocytosis and endocytosis. In nerve terminals, plasma membrane PIP~2~ levels decrease immediately upon Ca^2+^ influx ([@bib30]), and the Ca^2+^-dependent recruitment and stimulation of PIP5K may be essential for the synthesis of additional PIP~2~ needed to maintain rates of vesicle exocytosis and the endocytic retrieval of the vesicle membrane.

In conclusion, we present evidence that ARF6, through its regulation of PIP5K activity and PIP~2~ synthesis, controls at least two types of peripheral membrane trafficking events in PC12 cells ([Fig. 9](#fig9){ref-type="fig"}). Ca^2+^-dependent DCV exocytosis requires a plasma membrane pool of PIP~2~ whose synthesis may be acutely regulated by Ca^2+^-dependent activation of ARF6-dependent PIP5K enzymes. ARF6-dependent PIP5K enzymes also regulate endosome-plasma membrane trafficking. An imbalance in the ARF6-regulated endosome recycling pathway can result in the depletion of plasma membrane constituents such as PIP~2~ that are essential for DCV exocytosis.

Materials and methods
=====================

Constructs
----------

The plasmid pXS-SRα containing COOH-terminal HA-tagged human ARF6 wild type, Q67L, and T27N were provided by J. Donaldson of the National Institutes of Health (NIH), Bethesda, MD. Constructs encoding COOH-terminal fusions of wild-type, Q67L, and T27N ARF6 proteins with EGFP were generated by PCR using the primers 5′-CGATAAGCTTATATCCGACC-3′ and 5′-GGATACTGCAGGGATTTG-3′. The PCR product was cleaved with HindIII and PstI and inserted into HindIII-PstI--digested pEGFP-N1 (CLONTECH Laboratories, Inc.). All constructs were confirmed by sequencing. Coding sequences from a pBS plasmid containing HA-tagged murine full-length PIP5KIγ provided by H. Ishihara (University of Tokyo, Tokyo, Japan) were excised with HindIII and VspI and subcloned into pcDNA 3.1 (Invitrogen). HA-tagged murine Δ 344--635 PIP5KIγ was excised with HindIII and Alw441 and subcloned into pcDNA 3.1. The QuikChange^®^ Site-Directed Mutagenesis method (Stratagene) was used to generate the PIP5KIγ (S264A) mutant using the sense primer 5′-CACGTACAAGCGCAGGGCC[GCC]{.ul}AAGAAGGAGAAG-3′ (mutation site underlined). The pCMVGH plasmid encoding hGH was provided by H. Herweijer (Mirus Corp., Madison, WI) and an expression vector encoding PLC δ1 PH-GFP fusion protein provided by T. Balla (NIH).

Cell culture, transfection, and immunofluorescence
--------------------------------------------------

PC12 cells were cultured as described previously ([@bib21]). Cells were transfected with 50 μg DNA in cytomix buffer (120 mM KCl, 0.15 mM CaCl~2~, 10 mM KH~2~PO~4~, 2 mM EGTA, 5 mM MgCl~2~, 2 mM MgATP, 5 mM glutathione, and 25 mM Hepes, pH 7.6) using an electroporator apparatus (Electroporator II; Invitrogen) set at 1,000 μF and 330 V. 48 h after transfection, cells were washed with PBS, fixed with 4% formaldehyde (wt/vol), permeabilized with PBS containing 0.3% Triton X-100 or 0.2% saponin, and blocked in 10% FBS in PBS before antibody incubations. For PIP~2~ localization in intact cells using anti-PIP~2~ antibody, we used methods described previously ([@bib28]). For PIP~2~ localization in permeable PC12 cells, the permeable cells were tethered to glutaraldehyde-activated, poly-[l]{.smallcaps}-lysine--coated glass coverslips ([@bib49]). Antibodies used were polyclonal ARF6 (J. Donaldson and V. Klenchin; University of Wisconsin, Madison, WI); monoclonal and polyclonal HA (BAbCO); monoclonal FLAG M2 (Sigma-Aldrich); monoclonal SNAP-25 (Sternberger); monoclonal TGN38 (K. Howell, University of Colorado, Denver, Co); polyclonal mannosidase II (K. Moremen, University of Georgia, Athens, GA); monoclonal Rab11 (Zymed Laboratories); monoclonal PIP~2~ (K. Fukami, University of Tokyo); and monoclonal chromogranin B (W. Huttner, Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany). For transferrin uptake, transfected cells were incubated in medium containing 50 μg/ml Texas red--conjugated transferrin (Molecular Probes, Inc.) for 30 min at 37°C, washed in PBS, and fixed. Images were obtained on an laser-scanning confocal microscope (MRC-600; Bio-Rad Laboratories) with a 63× oil immersion objective. Quantitation of fluorescence was conducted with MetaMorph^®^ software (Universal Imaging Corp.) or SCION Image software (SCION Corp.).

Preparation of permeable PC12 cells and hGH secretion assays
------------------------------------------------------------

hGH release experiments were performed 48 h after transfection. Adherent PC12 cells were incubated in medium containing 5 μg/ml BFA (Epicentre) for 30 min at 37°C to inhibit constitutive hGH secretion without affecting Ca^2+^-dependent exocytosis. Cells were washed with Locke\'s solution (15 mM Hepes, pH 7.4, 145 mM NaCl, 5.6 mM KCl, 2.2 mM CaCl~2~, 5.6 mM glucose, 0.5 mM ascorbic acid, and 0.1% BSA) and incubated for 20 min with calcium-free Locke\'s solution or with elevated K^+^ solution (Locke\'s containing 59 mM KCl and 85 mM NaCl). Cell permeabilization and secretion assays were performed as described previously ([@bib21]; [@bib50]) in KGlu buffer (50 mM Hepes, pH 7.2, 105 mM potassium glutamate, 20 mM potassium acetate, and 2 mM EGTA) with 0.1% BSA at 30°C. Single-stage assays contained 2 mM MgATP, 0.7 mg/ml rat brain cytosol, and 10 μM free Ca^2+^. Two-stage assays used sequential incubations with MgATP plus cytosol and with Ca^2+^ plus cytosol with intervening washes. hGH secreted into medium or low speed supernatants and in 0.1% SDS-lysed cells was measured by radioimmunoassay (Nichols Institute Diagnostics).

Immunoprecipitation assays
--------------------------

After transfection, cells were washed and incubated for 5 min with Locke\'s or elevated K^+^ buffer before harvesting in lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100 or NP-40, 50 mM NaF, 1 mM sodium vanadate, 1 mM phenylmethylsulfonyl fluoride, and Boehringer complete protease inhibitor cocktail). Lysates were sedimented and supernatants were adsorbed with protein G--Sepharose beads before conducting 3--16-h incubations with HA tag mAbs immobilized on protein G--Sepharose beads. Beads were washed five times with lysis buffer and eluted in sample buffer containing 0.2 M DTT for analysis by immunoblotting with ARF6 or HA antibodies.
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